Connect with us

Technology

Piramal Pharma Limited Announces Results for Q4 and Full-year FY26

Published

on

MUMBAI, India, April 28, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026.

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars

Q4FY26

Q4FY25

YoY %

FY26

FY25

YoY %

Revenue from Operations

2,752

2,754

(0) %

8,869

9,151

(3) %

   CDMO

1,708

1,788

(4) %

4,915

5,447

(10) %

   CHG

755

705

7 %

2,703

2,633

3 %

   PCH

320

274

17 %

1,274

1,093

17 %

EBITDA

507

603

(16) %

1,135

1,580

(28) %

EBITDA Margin

18 %

22 %

13 %

17 %

PAT Before Expectational Item

167

154

9 %

(130)

91

NM

Exceptional Item1

(176)

–

NM

(196)

–

NM

PAT After Expectational Item

(9)

154

NM

(326)

91

NM

1. During the quarter, the management has recognized an impairment loss of ₹. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.  Accordingly, the carrying amount has been written down in full.

Key Highlights

Revenue – Growth was impacted by inventory destocking, slower early-stage order inflows in H1FY26, and softer traction in inhalation anesthesia across ex‑US markets. Adjusted for inventory destocking, we delivered YoY growth in Q4 and FY26.EBITDA Margin – Despite lower revenues, impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.Capex – US$94Mn invested in FY26 across growth and maintenance projects. Lexington and Riverview expansions on track. Seeing good customer interest.Net Debt – No increase over FY25.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biopharma funding seen from Sep’25,  is translating into good RFP momentum and healthy pick up in order inflows in our  CDMO business. In the CHG business, the recently completed Kenalog® acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e‑commerce.

Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT.”

Key Business Highlights

Contract Development and Manufacturing Organization (CDMO):

Healthy traction in RFPs and order inflows in H2FY26 driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in FY26) and M&A activity. (Industry Source)Overseas sites seeing rising demand from shifting customer geographical preferences and strong growth in differentiated areas such as ADC, HP API, on‑shore injectables and drug product capabilities.US$90Mn Capex on track to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites.Net Promoter Score of 60 – surpassing industry average. Meaningful improvement in execution with stronger performance across key operational matrices, driven by our operational excellence initiatives.209 customer site audits in FY26 vs. 165 in FY25 — highest ever. Reflecting heightened customer engagement, deeper technical interactions, and the growing complexity of programs we support.Maintained our Best-in-Class Quality Track Record – Successfully closed 38 regulatory inspections, including 3 USFDA inspections in FY26. Continue to maintain our ‘Zero OAI’ status.

Complex Hospital Generics (CHG):

Completed Kenalog® acquisition

– Upfront consideration of US$35Mn, and contingent consideration of up to US$65Mn.
– Broadens CHG portfolio, adds revenues with minimal incremental cost, and expands presence in US, Europe & Asia Pacific.
– Niche brand with complex manufacturing process. EBITDA margins in line with CHG business.

Inhalation Anesthesia (IA) 

– Continue to maintain leadership with 47% market share – up from 45% in Mar’24. (Source:- IQVIA)
– Initiated Sevoflurane supplies from lower cost Digwal facility in select RoW markets. Expect traction to build going ahead.

Intrathecal Therapy – Maintained our #1 Rank in intrathecal Baclofen segment in the US. (Source:- IQVIA)Injectable Pain Management – Continue to work with our supplier to resolve supply constraints.

Piramal Consumer Healthcare (PCH):

Power Brands continued growth momentum with 24% YoY growth in FY26, contributing 52% to PCH sales. Little’s, Lacto Calamine, CIR, and i-range remained primary driver of growth.New Product Launches – Fewer, high‑potential product launches with better success rates. Launched 31 new products and SKU in FY26. Focus on premiumization of portfolio.E-commerce sales grew at 48% rate YoY in FY26, contributing about 27% to PCH sales. Evolve product mix toward premium offerings and high margin channel (e.g. quick commerce).Invested about 12% of PCH sales on Media and Trade Promotion in FY26. Optimizing the media mix – Social Media, Television, Influencers, etc.

Consolidated Profit and Loss Statement

(in ₹ Crores or as stated)

Particulars

Quarterly

Full-year

Q4FY26

Q4FY25

YoY  %

Q3FY26

QoQ  %

FY26

FY25

YoY  %

Revenue from Operations

2,752

2,754

(0) %

2,140

29 %

8,869

9,151

(3) %

Other Income

46

42

10 %

43

7 %

213

135

58 %

Total Income

2,798

2,796

0 %

2,183

28 %

9,082

9,286

(2) %

Material Cost

1,056

955

11 %

786

34 %

3,239

3,232

0 %

Employee Expenses

586

612

(4) %

600

(2) %

2,416

2,307

5 %

Other Expenses

650

626

4 %

558

16 %

2,293

2,167

6 %

EBITDA

507

603

(16) %

239

112 %

1,135

1,580

(28) %

Interest Expenses

83

104

(20) %

89

(7) %

341

422

(19) %

Depreciation

218

243

(10) %

213

3 %

831

816

2 %

Share of Net Profit of Associates

14

16

(16) %

10

32 %

57

73

(22) %

Profit Before Tax

219

273

(20) %

(53)

NM

20

415

(95) %

Tax

52

119

(57) %

42

22 %

150

324

(54) %

Net Profit after Tax

167

154

9 %

(95)

NM

(130)

91

NM

Exceptional item1

(176)

–

NM

(41)

NM

(196)

–

NM

Net Profit after Tax after Exceptional Item

(9)

154

NM

(136)

NM

(326)

91

NM

During the quarter, the management has recognized an impairment loss of Rs. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.  Accordingly, the carrying amount has been written down in full.

Consolidated Balance Sheet

(in ₹ Cr.)

   Key Balance Sheet Items

As at

31-Mar-26

31-Mar-25

Total Equity

8,162

8,125

Net Debt

4,140

4,199

Total

12,302

12,324

Net Fixed Assets

9,784

9,110

    Tangible Assets

4,843

4,534

    Intangible Assets including goodwill

3,841

3,599

    CWIP (including IAUD2)

1,100

977

Net Working Capital

2,057

2,798

Other Assets3

462

416

Total Assets

12,302

12,324

2. IAUD – Intangible Assets Under Development; 3. Other Assets include Investments and Deferred Tax Assets (Net)

Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29th April 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and full-year FY26 Results.

The dial-in details for the call are as under:

Event

Location & Time

Telephone Number

Conference call on 29th April 2026

India – 09:30 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:00 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 05:00 AM

(London Time)

Toll free number

08081011573

Singapore – 12:00 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:00 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call –Click here

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit:  Piramal Pharma | LinkedIn

1. Includes one facility via PPL’s minority investment in Yapan Bio.

Logo – https://mma.prnewswire.com/media/1855206/5942698/Piramal_Pharma_Limited_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q4-and-full-year-fy26-302756234.html

Continue Reading

Technology

Cboe Clear U.S. Receives SEC Approval to Expand Clearing Capabilities

Published

on

By

SEC registration enables Cboe Clear U.S. to clear binary securities options alongside futures, positioning it to support innovation across the market

CHICAGO, Oct. 23, 2026 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced that Cboe Clear U.S., LLC (CCUS) has received temporary registration from the U.S. Securities and Exchange Commission (SEC) to operate as a Covered Clearing Agency.

The registration expands CCUS’s clearing capabilities beyond its existing authorities as a Commodity Futures Trading Commission (CFTC)-registered Derivatives Clearing Organization (DCO) to clear securities products in addition to futures and swaps products. Together with recent enhancements to its regulatory framework and product scope, the milestone positions CCUS to support innovation and emerging opportunities across a broad range of assets and markets.

CCUS will initially use its SEC registration to clear Cboe’s binary securities options tied to specified corporate key performance indicators (KPIs), which are planned to list on Cboe Options Exchange and be available on Robinhood in the fourth-quarter 2026. CCUS also recently received CFTC approval to clear margined futures broadly and continues to clear digital asset derivatives under its DCO designation.

“Clearing plays a critical role in bringing innovation to market,” said Dale Michaels, Head of Cboe Clear U.S. “These expanded capabilities position Cboe Clear U.S. to become an innovation lane to support new products and meet evolving customer needs, while maintaining the rigorous risk management standards that are fundamental to our business.”

These efforts complement Cboe’s longstanding partnership with The Options Clearing Corporation (OCC)® and Cboe’s continued commitment to supporting the established clearing infrastructure for traditional equity options.

The development builds on the growth of Cboe’s established European clearing business, where Cboe Clear Europe has become the leading pan-European equities central counterparty, while expanding into new services such as securities financing transaction clearing. Together, these advances demonstrate Cboe’s ability to extend its clearing capabilities across markets and asset classes.

To support its own future growth, CCUS has strengthened its infrastructure over the past year, including electing in June to become a Subpart C DCO. In doing so, CCUS is voluntarily adopting the enhanced standards the CFTC applies to systemically important DCOs for financial resources, risk management and operational resilience, aligning with those applied to leading global clearing organizations.

About Cboe Global Markets

Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world’s first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world’s leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.

Cboe Media Contacts

 

Cboe Analyst Contact

 

Angela Tu

+1-646-856-8734

atu@cboe.com

Tim Cave

+44 (0) 7593-506-719

tcave@cboe.com

Kenneth Hill, CFA

+1-312-786-7559

khill@cboe.com

CBOE-C
CBOE-OE

Cboe®, Cboe Global Markets®, and VIX ® are registered trademarks or service marks of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor’s Financial Services LLC. All other trademarks and service marks are the property of their respective owners. 

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our  clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cboe-clear-us-receives-sec-approval-to-expand-clearing-capabilities-302918297.html

SOURCE Cboe Global Markets, Inc.

Continue Reading

Technology

Hears Everything, Uploads Nothing: VoxNexus Launches Android’s First Low-Power On-Device Always-On Voice Artificial Intelligence (AI)

Published

on

By

VoxNexus’ new on-device ambient listening solution runs for 12 hours on 2.49% of a phone’s battery and never sends audio to the cloud

MADRID, Oct. 23, 2026 /PRNewswire/ — VoxNexus (www.VoxNexus.ai) released VoxEdge, an on-device voice stack that brings speech recognition, translation and speech synthesis to affordable Android devices, entirely offline. VoxEdge supports speech recognition in 36 languages, translation in 103 languages, and speech synthesis in 45 languages—all running with no connection, no data bundle, and no cloud token bills.

AI should work for everyone, not just for speakers of a handful of mainstream languages. Yet across much of Africa, voice AI has been held back by scarce training data and the lack of targeted fine-tuning. Everyday speech also includes code-switching and dialect variation, while cloud-based inference costs can make deployment at scale expensive. 

VoxNexus’s solutions run entirely on device, and every query is free once the model is installed on the device. Its speech recognition model has as few as 65 million parameters and achieves a lower word error rate than open-source models nearly ten times its size.

“Under-resource languages aren’t small languages. Hundreds of millions of people speak them. Until now, AI models just haven’t learned them yet,” said Charles Shi, CEO of VoxNexus.

VoxNexus also launched VoxSense, an on-device ambient listening solution that uses only 162 mAh for 12 hours of continuous listening, around 2.5% of a 6,500 mAh phone battery. By keeping all processing on device, VoxSense makes always-on listening practical without draining the battery and without sending any audio to the cloud. Developers and device makers can easily integrate it through a license and a simple SDK. Developers can request a free trial here: www.VoxNexus.ai.

VoxSense and VoxEdge were unveiled at the MediaTek Dimensity 9600 launch in Madrid on October 19.

Distributed by APO Group on behalf of VoxNexus AI. 

About VoxNexus:
VoxNexus builds AI that hears and speaks — for everyone, everywhere, all the time. Its audio intelligence runs entirely on-device, delivering low latency, built-in privacy, and zero token cost across any device with a chip. VoxNexus is headquartered in Singapore. Website: www.VoxNexus.ai. Contact: public@voxnexus.ai  

VoxNexus demonstrates live on-device speech recognition at the MediaTek Dimensity 9600 launch in Madrid on Oct. 19, 2026. Spanish and English conversations were transcribed in real time on the phone, with no cloud connection. (Photo: VoxNexus) 

Speaks Your Language, No Internet Needed: VoxNexus Brings On-Device Voice Artificial Intelligence (AI) in 100+ Languages to Affordable Android Devices

View original content:https://www.prnewswire.com/news-releases/hears-everything-uploads-nothing-voxnexus-launches-androids-first-low-power-on-device-always-on-voice-artificial-intelligence-ai-302918304.html

SOURCE VoxNexus AI

Continue Reading

Technology

team.blue extends €1.1 billion of its Term Loan B to 2032 in the largest software Euro term loan issuance in the last 12 months

Published

on

By

GHENT, Belgium, Oct. 23, 2026 /PRNewswire/ — team.blue, a leading pan-European provider of digital solutions for small and medium-sized businesses (SMBs) backed by Hg, CPP Investments and Sofina, today announces the successful pricing of an amendment and maturity extension for €1.1 billion of its existing €1.35 billion Term Loan B. The transaction priced on 22 October 2026, with the refinanced tranche extended from September 2029 to July 2032, reinforcing the Company’s prudent capital structure approach.

Strong demand from a broad group of institutional investors enabled team.blue to upsize the transaction twice in-market, taking the final deal size to €1.1 billion from a minimum initial launch size of €500 million, despite recent credit market volatility. Pro forma for the transaction, c.90% of team.blue’s term debt now matures in 2032.

The transaction comes at a time of significant momentum for team.blue, with continued double-digit revenue growth and strong cash generation supporting its deleveraging trajectory. Its products help Europe’s SMBs get online, get customers, get paid and stay compliant, and AI-enabled products are increasingly driving new customer growth. team.blue continues to innovate across its portfolio, from smarter tools within its brands to secure European cloud hosting built for customers’ growing AI workloads. Its category-leading SaaS brands are also integrating with leading AI assistants, bringing team.blue’s products to customers wherever they work.

Transaction highlights

The largest software Euro term loan issuance in the last 12 months€1.1 billion Term Loan B, borrowed by team.blue Finco S.à r.l., maturing July 2032Priced at E + 425bps with a 0% floor and an OID of 98.5Upsized twice from an initial €500 million, reflecting a heavily oversubscribed order bookCorporate and facility ratings of B3 (Moody’s) and B (S&P), both with stable outlooksBofA acted as Global Coordinator and Left Lead Physical Bookrunner, alongside Barclays. ABN AMRO, BNP Paribas, Citi, ING and J.P. Morgan acted as Bookrunners

Jonathan Thackray, Chief Financial Officer of team.blue, said:
“We set out to extend €500 million of our Term Loan B, and the depth of support from our institutional investor base allowed us to go much further. This reflects confidence in team.blue’s highly recurring, cash-generative model and our position as a leading digital partner for Europe’s SMBs. It gives us the flexibility to keep innovating and investing in the digital and AI-enabled tools our customers rely on.”

About team.blue
team.blue is the pan-European digital partner for small and medium businesses, serving more than 3.5 million customers in 24 countries. From web hosting, domains, email and cloud and AI infrastructure to e-commerce, engagement, payments and compliance tools, team.blue helps SMBs get online, get customers, get paid and stay compliant. Supported by more than 4,000 employees, team.blue’s vision is to make online business success simpler, with artificial intelligence at every step. 

View original content:https://www.prnewswire.co.uk/news-releases/teamblue-extends-1-1-billion-of-its-term-loan-b-to-2032-in-the-largest-software-euro-term-loan-issuance-in-the-last-12-months-302918306.html

Continue Reading

Trending